MP ADVISORS

kyowa hakko kirin sawai yoshindo fuji film kyowa kirin biologics aska pharma meiji seika daiichi sankyo nippon kayaku nichi-iko mitsubishi tanabe biosimilars mochida peg-gcsf filgrastim gene techno science toyobo biologics kissei umn pharma towa nipro pharma glp-1 inhibitor drivers of m&a/ licensing deals in nash clinical trial design in nash a typical nrf2 activator liver lysyl oxidase-like-2 (loxl2) inhibitor milestone failed nash drug omega-3-acid ethyl esters fxr agonist nafld non-alcoholic steatohepatitis hepatitis target for the treatment of nash nash synthetic fatty-acid/bile-acid conjugate (fabac) regulatory non-alcoholic fatty liver disease farnesoid x receptor (fxr) agonist galectin-3 inhibitors sns01-t velcade relapsed or refractory panobinostat morphosys celgene elotuzumab mds immunomodulatory multiple myeloma ixazomib amgen carfilzomib rocilinostat daratumumab proteasome inhibitor aml onyx revlimid kyprolis licensing opportunities for generic pharmaceutical novel product and formulation technology ndds drug delivery systems geomatrix flashtab glide sdi oradur eligen medusa lock tab colal arestat entericare and saber. geoclock pharma database global pharma consulting investment advisory service pharma consulting companies pharma market analysis pharma consulting firm pharma consulting services pharma expert pharma consulting